Centers for Disease Control and Prevention. Progress toward measles elimination – Japan, 1999–2008. Morbidity and Mortality Weekly Report
2008; 57: 1049–1052.
Centers for Disease Control and Prevention. Immunization of healthcare workers: recommendation of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). Morbidity and Mortality Weekly Report. Recommendations and Reports
1997; 46: 1–42.
Bolyard EA, et al.
Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infection Control and Hospital Epidemiology
1998; 19: 407–463.
Hatakeyama S, et al.
Prevalence of measles, rubella, mumps, and varicella antibodies among healthcare workers in Japan. Infection Control and Hospital Epidemiology
2004; 25: 591–594.
Asari S, et al.
Seroprevalence survey of measles, rubella, varicella, and mumps antibodies in health care workers and evaluation of a vaccination program in a tertiary care hospital in Japan. American Journal of Infection Control
2003; 31: 157–162.
Vagholkar S, et al.
Healthcare workers and immunity to infectious diseases. Australian and New Zealand Journal of Public Health
2008; 32: 367–371.
Fedeli U, Zanetti C, Saia B. Susceptibility of healthcare workers to measles, mumps rubella and varicella. Journal of Hospital Infection
2002; 51: 133–135.
Celikbas A, et al.
Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
American Journal of Infection Control
2006; 34: 583–587.
Almuneef MA, et al.
Seroprevalence survey of varicella, measles, rubella, and hepatitis A and B viruses in a multinational healthcare workforce in Saudi Arabia. Infection Control and Hospital Epidemiology
2006; 27: 1178–1183.
Sadzot-Delvaux C, et al.
Varicella vaccination in Japan, South Korea, and Europe. Journal of Infectious Diseases
2008; 197 (Suppl. 2): 185–190.
Kaetsu A, et al.
An outbreak of measles in Saitama City in 2007. What is the vaccination strategy to eliminate measles in Japan?
Journal of Infection and Chemotherapy
2008; 14: 291–295.
Clifford HD, et al.
Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from Mozambique. Vaccine
2012; 30: 6180–6185.
de Melker H, et al.
The seroepidemiology of measles in Western Europe. Epidemiology and Infection
2001; 126: 249–259.
Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. New England Journal of Medicine
2007; 357: 1903–1915.
Lee MS, et al.
Protective titres of measles neutralising antibody. Journal of Medical Virology
2000; 62: 511–517.
Tharmaphornpilas P, et al.
Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme. Journal of Health, Population and Nutrition
2009; 27: 80–86.
Maple PA, et al.
Comparison of the performance of the LIAISON VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for LIAISON assay. Journal of Clinical Virology
2009; 44: 9–14.
Skendzel LP. Rubella immunity. Defining the level of protective antibody. American Journal of Clinical Pathology
1996; 106: 170–174.
Matter L, Kogelschatz K, Germann D. Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. Journal of Infectious Diseases
1997; 175: 749–755.
Backhouse JL, et al.
Evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus. Clinical and Vaccine Immunology
2006; 13: 764–767.
Davidkin I, et al.
Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. Journal of Infectious Diseases
2008; 197: 950–956.